Ji Pengtian, He Junjun
Department of Oncological Radiotherapy, Huzhou Central Hospital, Affiliated Central Hospital of Huzhou University, The Fifth School of Clinical Medicine of Zhejiang Chinese Medical University, Huzhou, Zhejiang, 313000, China.
Clinical Laboratory, Huzhou Traditional Chinese Medicine Hospital Affiliated to Zhejiang Chinese Medical University, Huzhou, Zhejiang, China.
Biomark Med. 2024;18(7):345-356. doi: 10.2217/bmm-2023-0629. Epub 2024 Apr 16.
The present work focused on evaluating the systemic immune-inflammation index (SII) for its role in predicting endometrial cancer (EC) patient prognosis by meta-analysis. SII's role in predicting the prognosis of EC patients was analyzed by calculating combined hazard ratios (HRs) and 95% CIs. As revealed by combined analysis, an increased SII predicted poor overall survival (HR = 2.01; 95% CI = 1.58-2.57; p < 0.001) as well as inferior progression-free survival (HR = 1.87; 95% CI = 1.36-2.58; p < 0.001) of EC. An increased SII score significantly predicted poor overall survival and progression-free survival in subjects with EC. The SII is suitable for predicting short- and long-term prognoses of patients with EC.
本研究通过荟萃分析，聚焦于评估全身免疫炎症指数（SII）在预测子宫内膜癌（EC）患者预后中的作用。通过计算合并风险比（HR）和95%置信区间（CI），分析SII在预测EC患者预后中的作用。综合分析显示，SII升高预示着EC患者的总生存期较差（HR = 2.01；95% CI = 1.58 - 2.57；p < 0.001）以及无进展生存期较差（HR = 1.87；95% CI = 1.36 - 2.58；p < 0.001）。SII评分升高显著预示着EC患者的总生存期和无进展生存期较差。SII适用于预测EC患者的短期和长期预后。
